Overview
| Specialty | Neurology |
|---|---|
| Clinical Interests | Multiple Sclerosis |
| Neuroimmunology | |
| Neurology | |
| Languages | English |
| Gender | Male |
| fred.lublin@mssm.edu | |
| Education and Training | MD, Jefferson Medical College |
| Residency, Internal Medicine, Bronx Municipal Hospital Center | |
| Residency, Neurology, New York Hospital | |
| Awards | 2001 Attending of the Year Award Mount Sinai Medical Center Neurology Residents |
| 2000 - Present Chairman, Research Programs Advisory Committee National Multiple Sclerosis Society |
|
| 1999 Hope Award National Multiple Sclerosis Society, Delaware Valley Chapter |
|
| 1999 McEwan Visiting Professorship & Lecture in Neurology University of Toronto |
|
| 1996 Milestone Award National Multiple Sclerosis Society, Delaware Valley Chapter |
Fred D. Lublin, MD is the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center. He is an internationally renowned authority on the clinical and scientific aspects of MS and one of the foremost experts in experimental therapies.
As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. In 2005, Dr. Lublin received a $25-million grant from the National Institutes of Health (NIH) to conduct a nationwide multi-center study on the effectiveness of combining two disease-modifying drugs. This grant was renewed in 2008, bringing the total allocated by the NIH to $44-million, one of the largest grants ever given for MS research.
Learn more about Dr. Lublin's work as Principal Investigator in the CombiRx clinical trial, as this study is known, in Inside Mount Sinai. He is also currently involved in several new clinical research protocols on promising agents for treating various aspects of MS.
Dr. Lublin was chairman of the National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new MS drugs; and he is currently chair of the Clinical Advisory Committee of the New York City Chapter of the National MS Society. Dr. Lublin and his colleagues at the National MS Society (USA) have redefined the clinical course definitions of MS.
Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the NIH, as well as to pharmaceutical and biotech companies in all phases of drug development, and in preparation for drug presentation to the FDA and its advisory panels.
Dr. Lublin received his medical degree at Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

